옵션 체인은 다양한 행사가격과 만기일에 대한 Adial Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Adial Pharmaceuticals에 대한 시장 심리를 평가합니다..

Adial Pharmaceuticals (NASDAQ:ADIL) 주식, 옵션 체인

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

Government

News

Regulations

BURU

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

PRQR

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Macro Economic Events

Econ #s

Economics

US PCE Price index (YoY) (May) +2.3% vs +2.3% Est.

USA Core PCE Price Index (MoM) (May) +0.2% vs +0.1% Est.

PCE Price Index MoM For For May 0.1% Vs 0.1% Expected

Macro Notification

General

Core PCE Price Index (YoY) (May) +2.7% vs +2.6% Est.

JMP Securities analyst Patrick Walravens reiterates Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Market Outperform and maintains $17 price target.

JMP Securities Reiterates Market Outperform on Sprinklr, Maintains $17 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Jefferies analyst Peter Abramowitz initiates coverage on Armada Hoffler Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) with a Buy rating and announces Price Target of $8.

Initiation

Jefferies Initiates Coverage On Armada Hoffler Properties with Buy Rating, Announces Price Target of $8

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) showcased an <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence (AI) model</a> designed to identify gastric cancer, co-developed by Alibaba&#8217;s Damo Academy and the Zhejiang Cancer Hospital.
The model can detect gastric cancer, even in early stages, by scanning computed tomography (CT) images. The AI model known as Grape derived its name from the &#8220;gastric cancer risk assessment procedure.&#8221;
Grape can analyze three-dimensional CT scans to detect and segment gastric cancer, also known as stomach cancer, SCMP <a target="_blank" href="https://www.scmp.com/tech/article/3315931/alibaba-touts-worlds-first-ai-model-detect-stomach-cancer-even-early-stages" rel="noreferrer noopener">reported</a> on Thursday.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46069690/alibaba-accelerates-global-ai-push-targets-overseas-data-centers" rel="noreferrer noopener">Alibaba Accelerates Global AI Push, Targets Overseas Data Centers</a>
Diagnosis of gastric cancer currently requires an endoscopy, prompting the insertion of a camera and tiny biopsy instruments through the throat.
Citing a paper published in Nature Medicine on Tuesday, SCMP reported that the Grape model significantly outperformed radiologists.
This initiative underscores Alibaba&#8217;s strategic move to unlock value by integrating AI technology into its various operations, including healthcare.
Following a similar approach, Alibaba had already made a breakthrough in detecting pancreatic cancer in 2023, showcasing a growing focus on applying its AI expertise to critical medical challenges.
Beyond healthcare, Alibaba is also making waves in the general AI landscape. Last week, Alibaba revealed new Qwen3 AI models, <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45975004/alibaba-updates-llms-to-power-ai-on-apple-devices-in-china" rel="noreferrer noopener">signaling a possible</a> collaboration or rollout with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in China amid rising local AI demand.
Alibaba co-founder and Chair&nbsp;Joe Tsai opted to <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45925331/alibaba-co-founder-sees-open-source-qwen-driving-cloud-demand" rel="noreferrer noopener">open-source its</a> Qwen models, citing their potential to drive demand for&nbsp;AI&nbsp;applications and cloud computing.
Open source gives the public access to a software program&#8217;s source code, allowing third-party developers to modify or scale up its capabilities.
IMARC Group&nbsp;expects&nbsp;the global <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45816525/alibaba-releases-new-open-source-ai-models-with-multilingual-and-code-support" rel="noreferrer noopener">open-source intelligence</a> market to reach&nbsp;$58.0 billion&nbsp;by 2033, at a&nbsp;CAGR of 15.93%&nbsp;from 2025 to 2033.
Price Action:&nbsp;BABA stock traded higher by 0.11% to $114.06 premarket at&nbsp;the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Asia

Health Care

Tech

Media

AAPL

BABA

Alibaba's AI Model Outperforms Radiologists In Early Gastric Cancer Detection

TD Securities analyst John Mould initiates coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Buy rating and announces Price Target of C$74.

TSX:FTS

TD Securities Initiates Coverage On Fortis with Buy Rating, Announces Price Target of C$74

Editor&#8217;s Note: The article has been updated to include comments from the office of Prime Minister Benjamin Netanyahu.
U.S. President&nbsp;Donald Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;are reportedly working on a plan to end the ongoing war in Gaza and expand the Abraham Accords, with new countries joining the peace agreement.
What Happened: The plan, as reported by&nbsp;Israel Hayom, would require Israel&nbsp;to commit to supporting a&nbsp;future Palestinian state. This proposal was discussed during a phone call between Trump and Israeli Prime Minister&nbsp;Benjamin Netanyahu&nbsp;on Monday, <a href="https://www.timesofisrael.com/netanyahu-trump-said-working-on-plan-to-end-gaza-war-and-expand-abraham-accords/">stated </a>The Times Of Israel. 
The leaders have reportedly agreed to bring the Gaza war to an end within a two-week timeline, which would require Israel to cease its military operations&nbsp;and Hamas to release the&nbsp;remaining 50 hostages. Following this, the leadership of the Palestinian group would be exiled, and the governance of the war-ravaged region would be jointly undertaken by four Arab nations, including the UAE and Egypt.
The plan also includes provisions for the rehabilitation of the Gaza Strip, absorption of Gazans wishing to emigrate by several undisclosed countries and Israel&#8217;s&nbsp;backing for a future two-state&nbsp;solution contingent on reforms&nbsp;by the Palestinian Authority. In&nbsp;exchange, Washington would acknowledge Israeli sovereignty over certain areas of the West Bank.
Once the war ends and Israel reaffirms its commitment to a two-state solution, Saudi Arabia and Syria are expected to establish diplomatic ties with Israel under the Abraham Accords, with other Arab and Muslim countries likely to follow.
Meanwhile, Netanyahu&#8217;s office <a href="https://www.columbusjewishnews.com/jns/pmo-denies-israel-us-talks-on-two-state-solution-took-place/article_45953d88-523b-547b-a1b0-4f46044e5a95.html">said</a>, &#8220;The conversation&#8230;did not take place." 
 "Israel was not presented with the political proposal supposedly described in the article, and it obviously did not agree to it."
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/health-care/25/06/46131597/bill-gates-says-he-knows-for-a-fact-that-more-children-will-die-due-to-us-health-aid-cuts-and-he" target="_blank" rel="noreferrer noopener">Bill Gates Says He Knows For A &#8216;Fact&#8217; That More Children Will Die Due To US Health Aid Cuts And He&#8217;s Taking The &#8216;Proof&#8217; To Congress</a>
Why It Matters: This development comes amid other significant events in the region. Trump recently&nbsp;urged Israel to cancel or pardon <a href="https://www.benzinga.com/news/politics/25/06/46108200/trump-calls-for-canceling-netanyahus-witch-hunt-corruption-trial-calls-it-a-travesty-of-justice">Netanyahu&#8217;s corruption</a> trial, calling it a &#8220;witch hunt.&#8221; This public support from Trump could have implications for the Israeli political landscape.
Meanwhile, U.S. Senator&nbsp;Elizabeth Warren&nbsp;recently&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46068097/elizabeth-warren-presses-marco-rubio-over-potential-500-million-usaid-diversion-to-controversial-gaza-foundation-report">raised concerns</a> about a proposal&nbsp;to redirect $500 million from USAID to the Gaza Humanitarian Foundation, a controversial organization. This proposal, if implemented, could have a significant impact on the humanitarian situation in Gaza.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://www.benzinga.com/news/politics/25/06/46132996/marco-rubio-says-everything-under-the-mountains-is-in-bad-shape-rubbishes-claim-trump-strikes-only-bought-iran-time">Marco Rubio Says &#8216;Everything Under The Mountains Is In Bad&#8217; Shape, Rubbishes Claim Trump Strikes Only Bought Iran Time</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump And Israel's Netanyahu Working On Plan To End Gaza War, Expand Abraham Accords: Report (UPDATED)

WIIM

ACHV

Achieve Life Sciences shares are trading lower after the company announced a $45 million public offering.

JMP Securities analyst Andrew Boone upgrades Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) from Market Perform to Market Outperform and maintains the price target from $220 to $220.

Upgrades

GOOGL

JMP Securities Upgrades Alphabet to Market Outperform, Maintains Price Target to $220

AEMD

Aethlon Medical shares are trading lower after the company reported a Q4 EPS miss.

Legal

Press Releases

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Financing

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

Earnings

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting

IPOs

Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Comments

Adial Pharmaceuticals

Adial Pharmaceuticals (ADIL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌